RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1-Reference-Cited by-同舟云学术

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

Published:2017-10-23 Issue:6 Volume:37 Page:821-832
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Chen S-H,Gong X,Zhang Y,Van Horn R D,Yin T,Huber L,Burke T F,Manro J,Iversen P W,Wu W,Bhagwat S V,Beckmann R P,Tiu R V,Buchanan S G,Peng S-B

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2017384.pdf

Reference48 articles.

1. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ . Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 2014; 13: 828–851.

2. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761–774.

3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–954.

4. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012; 22: 668–682.

5. Lito P, Rosen N, Solit DB . Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013; 19: 1401–1409.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling;International Journal of Cancer;2024-07-12

3. Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine;International Journal of Molecular Sciences;2024-07-05

4. A comprehensive overview of the molecular features and therapeutic targets in BRAF^V600E‐mutant colorectal cancer;Clinical and Translational Medicine;2024-07

5. Targeting RAF dimers in RAS mutant tumors: From biology to clinic;Acta Pharmaceutica Sinica B;2024-05